Accelerating the Progress of Scleroderma Research
CONQUEST is a phase 2b, international, multicenter, platform clinical trial developed by the SRF and partner biopharmaceutical companies to study multiple therapies for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD). The goal of CONQUEST is to accelerate the development and approval of the most effective therapies to treat SSc-ILD.
CONQUEST is anticipated to start enrolling patients in late summer 2023. Individuals who have SSc-ILD may be eligible to participate in CONQUEST. Further information about CONQUEST will be available in the coming months.
